UroGen's ZUSDURI Revenue Doubles as Commercial Momentum Accelerates
Event summary
- ZUSDURI revenue surged 109% quarter-over-quarter to $29.2 million in Q1 2026, driven by broader adoption following the permanent J Code effective January 1, 2026.
- JELMYTO revenue grew 7% year-over-year to $21.7 million in Q1 2026.
- UroGen plans to submit an NDA for UGN-103 in the second half of 2026, with potential FDA approval in 2027.
- The company expanded its debt facility with Pharmakon Advisors, securing $200 million in additional financing.
- UroGen reported a net loss of $23.6 million in Q1 2026, an improvement from a $43.8 million loss in the same period last year.
The big picture
UroGen's strong Q1 2026 results highlight the accelerating commercial adoption of ZUSDURI, reflecting growing clinical confidence in the non-surgical treatment for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. The company's strategic focus on expanding its pipeline, including next-generation products like UGN-103 and UGN-104, positions it to capitalize on the significant commercial opportunity in uro-oncology. The expanded debt facility provides non-dilutive capital to support these initiatives, though the company must balance financial discipline with aggressive growth ambitions.
What we're watching
- Commercial Momentum
- Whether UroGen can sustain the rapid adoption of ZUSDURI beyond the initial launch phase, particularly as more prescribers integrate it into routine urology practice.
- Pipeline Progress
- The pace at which UGN-103 advances through regulatory approval and how it may enhance UroGen's market position in uro-oncology.
- Financial Strategy
- How UroGen manages its expanded debt facility and whether the additional capital will support long-term growth without compromising financial stability.
Related topics